← SynDRA
VISMODEGIB
SynDRA canonical compound SYN0012015 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SMO |
|---|
| Mechanism of action | Smoothened receptor antagonist |
|---|
| Indication | basal cell carcinoma (BCC) |
|---|
| Disease area | oncology |
|---|
All known targets
- SMO
- ABCG2
- ABCB1
- CYP2C19
- CYP2C8
- DHH
- IHH
- PTCH1
- SHH
- Shh
- Smo
Mechanisms of action (all sources)
- hedgehog pathway inhibitor
- Smoothened receptor antagonist
- SMO inhibitor
- Smoothened homolog inhibitor
- SMO ANTAGONIST
- SMO MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALB
- USP28
- HTR1A
- ACHE
- NPY1R
- NEIL2
- NEIL1
- MPG
- MLNR
- MC4R
- MC3R
- MAOA
- KCNH2
- NR3C1
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HRH3
- HRH2
- HRH1
- NR1I2
- OPRD1
- NTHL1
- GPR119
- TDG
- TBXA2R
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- SCN5A
- S1PR1
- PTGS2
- PTGS1
- PORCN
- PGR
- PDE4D
- PDE4A
- PDE3A
Drug classes
- Smoothened Receptor Antagonists
- Hedgehog Pathway Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- ERIVEDGE
- Erivedge
- erivedge
- GDC-0449
- RG3616
- NSC-747691
- NSC-755986
- GDC 0449
- Vismodegib (GDC-0449)
- HhAntag691
- GDC0449
- UNII-25X868M3DS
- CHEMBL473417
- CHEBI:66903
- 25X868M3DS
- NSC755986
- AK-77261
- C19H14Cl2N2O3S
- Erivedge (TN)
- Vismodegib (SHH inhibitor)
- NSC 747691
- GDC-0449 (Vismodegib)
- Vismodegib [USAN]
- Vismodegib [USAN:INN]
- vismodegibum
- HSDB 8130
- R-3616
- NSC747691
- Hh-Antag691
- HhAntag 691
- Vismodegib, free base
- RG-3616
- methanesulfonylbenzamide
- VISMODEGIB [MI]
- VISMODEGIB [INN]
- Vismodegib (USAN/INN)
- VISMODEGIB [VANDF]
- Vismodegib; GDC-0449
Reported adverse events
- Ageusia
- Alopecia
- Arthralgia
- Constipation
- Dysgeusia
- Fatigue
- Muscle spasms
- Nausea
- Stevens-Johnson syndrome
- Vomiting
- Decreased appetite
- Drug-induced liver injury
Look up VISMODEGIB in the interactive SynDRA portal →